Results 161 to 170 of about 31,766 (260)

Global Pharmacovigilance of Aesthetic Botulinum Toxin Type A: Analysis of Adverse Event Reports From the USA, Europe, Canada, and Australia. [PDF]

J Cosmet Dermatol
Zargaran A, Zargaran D, Pirayesh A, Woollard A, Mosahebi A.   +4 more
europepmc   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source

Ecopharmacovigilance and pharmacovigilance: an analysis of environment-related reporting in VigiBase. [PDF]

Environ Sci Pollut Res Int
Mitchell J, Maza Larrea J, Dzidzornu ED, Pandit J, Cherian JJ, Massouh R.   +5 more
europepmc   +1 more source

International Dermoscopy Society consensus recommendations for the management of lentigo maligna

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Lentigo maligna (LM) poses diagnostic and therapeutic challenges amid rising incidence and limited high‐quality evidence. This international expert consensus provides pragmatic, evidence‐based and expertise‐informed guidance on LM diagnosis and management.
Ana‐Maria Forsea, Riccardo Pampena, Bengu Nisa Akay, Zoe Apalla, Giuseppe Argenziano, Giulia Briatico, Ralph Braun, Horacio Cabo, Raul Cabrera, Cristina Carrera, Elisa Cinotti, Claudio Conforti, Enzo Errichetti, Gerardo Ferrara, Roberta Giuffrida, Stefania Guida, Pascale Guitera, Allan C. Halpern, Stephen Heyes, Rainer Hofmann‐Wellenhof, Angela M. Hong, Natalia Jaimes, Raimonds Karls, Harald Kittler, Teresa Kränke, Konstantinos Liopyris, Jie Liu, Caterina Longo, Josep Malvehy, Ashfaq A. Marghoob, Hoda Moneib, David Moreno Ramirez, Elvira Moscarella, Eduardo Nagore, Cristian Navarrete‐Dechent, John Paoli, Giovanni Pellacani, Ketty Peris, Susana Puig, Cliff Rosendahl, Lidia Rudnicka, Ahmed Sadek, Philippe Saiag, Gabriel Salerni, Alon Scope, Hans Peter Soyer, Michela V. Starace, Wilhelm Stolz, David L. Swanson, Luc Thomas, Philipp Tschandl, Iris Zalaudek, Aimilios Lallas   +52 more
wiley   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. [PDF]

Clin Pharmacol Ther
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source

Patch Testing Is Useful in Patients With Lamotrigine‐Induced Cutaneous Adverse Drug Reactions

Contact Dermatitis, EarlyView.
E. Bertazzo, N. Laviec, C. Toussaint, P. Sanchez‐Pena, B. Milpied   +4 more
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Chemical Motifs Associated with FAERS-Derived Severe Cutaneous Adverse Reaction Disproportionality Signals: An Interpretable Pharmacovigilance-Driven Cheminformatics Study. [PDF]

Int J Mol Sci
Uesawa Y, Inden K, Asada M.
europepmc   +1 more source

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény   +10 more
wiley   +1 more source

Reclaiming Pharmacovigilance: Bridging the Evidence-Practice Gap in Psychopharmacology. [PDF]

J Eval Clin Pract
De Las Cuevas C.
europepmc   +1 more source